Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Colombo I, Lheureux S, Oza AM.

Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018. Review.

2.

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Sen T, Gay CM, Byers LA.

Transl Lung Cancer Res. 2018 Feb;7(1):50-68. doi: 10.21037/tlcr.2018.02.03. Review.

3.

NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains.

Langelier MF, Zandarashvili L, Aguiar PM, Black BE, Pascal JM.

Nat Commun. 2018 Feb 27;9(1):844. doi: 10.1038/s41467-018-03234-8.

4.

PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation.

Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ, Petermann E, Lakin ND.

Nat Commun. 2018 Feb 21;9(1):746. doi: 10.1038/s41467-018-03159-2.

5.

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR.

Mol Oncol. 2018 Apr;12(4):561-576. doi: 10.1002/1878-0261.12185. Epub 2018 Mar 15.

6.

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC.

Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20. Review.

7.

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2017 Dec 17;9(3):3908-3921. doi: 10.18632/oncotarget.23386. eCollection 2018 Jan 9.

8.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.

PMID:
29395061
9.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

10.

Proteomic Analysis of the Downstream Signaling Network of PARP1.

Zhen Y, Yu Y.

Biochemistry. 2018 Jan 30;57(4):429-440. doi: 10.1021/acs.biochem.7b01022. Epub 2018 Jan 19.

PMID:
29327913
11.

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

Tutt A.

Ann Oncol. 2018 Jan 1;29(1):18-21. doi: 10.1093/annonc/mdx775. No abstract available.

12.

PARP inhibition causes premature loss of cohesion in cancer cells.

Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.

Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28.

13.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

14.

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Ferrari N, Granata I, Capaia M, Piccirillo M, Guarracino MR, Venè R, Brizzolara A, Petretto A, Inglese E, Morini M, Astigiano S, Amaro AA, Boccardo F, Balbi C, Barboro P.

Cell Commun Signal. 2017 Dec 8;15(1):51. doi: 10.1186/s12964-017-0206-x.

15.

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.

Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.

16.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

PMID:
29180466
17.

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.

Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S.

Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017.

18.

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Borst GR, Kumareswaran R, Yücel H, Telli S, Do T, McKee T, Zafarana G, Jonkers J, Verheij M, O'Connor MJ, Rottenberg S, Bristow RG.

Oncotarget. 2017 Sep 15;8(50):87638-87646. doi: 10.18632/oncotarget.20936. eCollection 2017 Oct 20.

19.

ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K.

PLoS One. 2017 Nov 17;12(11):e0188320. doi: 10.1371/journal.pone.0188320. eCollection 2017.

20.

Current status of poly(ADP-ribose) polymerase inhibitors and future directions.

Ohmoto A, Yachida S.

Onco Targets Ther. 2017 Oct 26;10:5195-5208. doi: 10.2147/OTT.S139336. eCollection 2017. Review.

Supplemental Content

Support Center